GlassScriptPhysician profile
Marci A Kowalewski
NPI 1477658235
$12,297.25
in general payments reported to CMS, 2019-2025
38 companies · $2,444 in 2025
The $2,444 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,472 · 2022: $2,160 · 2023: $2,685 · 2024: $2,536 · 2025: $2,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,605 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,605.33 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,749.38 | 2021-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $1,528.65 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,158.55 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,035.28 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $927.66 | 2021-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Lilly USA, LLC | $863.30 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $754.96 | 2021-2025 | |
| Dexcom, INC. | $522.09 | 2021-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $423.38 | 2022-2025 | Rexulti |
| Daiichi Sankyo INC. | $310.14 | 2021-2023 | Injectafer |
| Abbott Laboratories | $290.22 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $250.81 | 2022-2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $245.32 | 2021-2023 | |
| Esperion Therapeutics, INC. | $202.73 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $199.69 | 2022-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $177.64 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $174.51 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Astellas Pharma US INC | $169.63 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $165.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $138.21 | 2021-2024 | Eliquis |
| Pfizer INC. | $130.00 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $126.08 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $118.42 | 2024-2025 | Zenpep, Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $95.09 | 2022-2023 | Trintellix |
| Eisai INC. | $68.82 | 2021 | |
| Kaleo, INC. | $64.93 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $59.96 | 2021-2022 | |
| Myriad Women'S Health, INC. | $49.74 | 2023 | Myrisk |
| Impel Pharmaceuticals INC. | $44.58 | 2023 | Trudhesa |
| Teleflex LLC | $37.45 | 2024 | Urolift |
| Bayer Healthcare Pharmaceuticals INC. | $32.96 | 2025 | |
| Amarin Pharma, INC. | $31.81 | 2021 | |
| Axsome Therapeutics, INC. | $30.78 | 2023 | Auvelity |
| Sumitomo Pharma America, INC. | $29.91 | 2024 | Gemtesa |
| Axonics, INC. | $29.00 | 2022-2023 | Axonics |
| Arbor Pharmaceuticals, INC. | $28.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marci Kowalewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.